Stock Research for DCTH

DCTH

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

DCTH Stock Chart & Research Data

The DCTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DCTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


DCTH Due diligence Resources & Stock Charts

The DCTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DCTH Detailed Price Forecast - CNN Money CNN View DCTH Detailed Summary - Google Finance
Yahoo View DCTH Detailed Summary - Yahoo! Finance Zacks View DCTH Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View DCTH Trends & Analysis - Trade-Ideas Barrons View DCTH Major Holders - Barrons
NASDAQ View DCTH Call Transcripts - NASDAQ Seeking View DCTH Breaking News & Analysis - Seeking Alpha
Spotlight View DCTH Annual Report - CompanySpotlight.com OTC Report View DCTH OTC Short Report - OTCShortReport.com
TradeKing View DCTH Fundamentals - TradeKing Charts View DCTH SEC Filings - Bar Chart
WSJ View Historical Prices for DCTH - The WSJ Morningstar View Performance/Total Return for DCTH - Morningstar
MarketWatch View the Analyst Estimates for DCTH - MarketWatch CNBC View the Earnings History for DCTH - CNBC
StockMarketWatch View the DCTH Earnings - StockMarketWatch MacroAxis View DCTH Buy or Sell Recommendations - MacroAxis
Bullish View the DCTH Bullish Patterns - American Bulls Short Pains View DCTH Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View DCTH Stock Mentions - StockTwits PennyStocks View DCTH Stock Mentions - PennyStockTweets
Twitter View DCTH Stock Mentions - Twitter Invest Hub View DCTH Investment Forum News - Investor Hub
Yahoo View DCTH Stock Mentions - Yahoo! Message Board Seeking Alpha View DCTH Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for DCTH - SECform4.com Insider Cow View Insider Transactions for DCTH - Insider Cow
CNBC View DCTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DCTH - OTC Markets
Yahoo View Insider Transactions for DCTH - Yahoo! Finance NASDAQ View Institutional Holdings for DCTH - NASDAQ


Stock Charts

FinViz View DCTH Stock Insight & Charts - FinViz.com StockCharts View DCTH Investment Charts - StockCharts.com
BarChart View DCTH Stock Overview & Charts - BarChart Trading View View DCTH User Generated Charts - Trading View




Latest Financial News for DCTH


Data on Delcath’s PHP Therapy presented at CIRSE 2018
Posted on Monday September 24, 2018

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that data from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, was presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. The study entitled Survival and Response of Patients with Metastatic Ocular Melanoma after Chemosaturation Percutaneous Hepatic Perfusion was conducted by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.


Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
Posted on Thursday September 13, 2018

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights will be exercisable until 5:00 p.m. Eastern time on September 26, 2018, though most broker dealers will require holders of rights to exercise in advance of this date. Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock.


Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
Posted on Tuesday September 04, 2018

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been accepted for publication in the journal European Radiology. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicenter Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France.  The results have been previously presented to a Delcath sponsored Key Opinion Leaders forum, where investigators agreed the data "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation." A summary of these findings was later presented to the Cholangiocarcinoma Foundation 2017 annual meeting and have provided a basis for the protocol design for the Company’s registration trial in ICC, which has commenced.  Data from this analysis is embargoed until publication.


Delcath Announces Extension of Rights Offering Period to September 26, 2018
Posted on Tuesday August 28, 2018

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an additional 30-day period, until 5:00 PM Eastern time on September 26, 2018. Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.  In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.